TIDMRUA

RNS Number : 2425K

RUA Life Sciences PLC

31 August 2021

RUA Life Sciences Plc

("RUA Life Sciences", the "Company" or the "Group")

Result of AGM

RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon (TM) ), announces that all resolutions put to shareholders at its Annual General Meeting held earlier today, were duly passed. In light of the risks associated with the coronavirus pandemic, the Board reluctantly advised shareholders against attending in person and the vote was taken by way of a poll.

The full details of votes cast are set out below:

 
 Res      Votes        %      Votes Against     %     Votes Total   % I.S.C.   Votes Withheld 
  No.      For 
                   --------                  ------ 
  01    5,401,382   100.00%               0   0.00%     5,401,382      24.35                0 
-----              --------                  ------                ---------  --------------- 
  02    5,360,836   99.26%           39,726   0.74%     5,400,562      24.34              820 
-----              --------                  ------                ---------  --------------- 
  03    5,401,382   100.00%               0   0.00%     5,401,382      24.35                0 
-----              --------                  ------                ---------  --------------- 
  04    5,401,366   100.00%              16   0.00%     5,401,382      24.35                0 
-----              --------                  ------                ---------  --------------- 
  05                                          WITHDRAWN 
-----  -------------------------------------------------------------------------------------- 
  06    5,400,370   99.98%            1,000   0.02%     5,401,370      24.35               12 
-----              --------                  ------                ---------  --------------- 
  07    5,273,860   99.86%            7,494   0.14%     5,281,354      23.81          120,028 
-----              --------                  ------                ---------  --------------- 
  08    5,386,892   99.73%           14,348   0.27%     5,401,240      24.35              142 
-----              --------                  ------                ---------  --------------- 
  09    5,392,646   99.84%            8,594   0.16%     5,401,240      24.35              142 
-----              --------                  ------                ---------  --------------- 
 

In advance of the AGM, questions were received from shareholders unable to attend the meeting due to the advice given. Those questions and answers will shortly be published on the Company's website.

For further information contact:

RUA Life Sciences

Bill Brown, Chairman Tel: +44 (0)1294 317073

   Dr Caroline Stretton, Group MD                                           Tel: +44 (0)1294 317073 
   Shore Capital (Nominated Adviser and Joint Broker)     Tel: +44 (0)20 7408 4080 

Tom Griffiths/David Coaten

   Cenkos Securities plc (Joint Broker)                                Tel: +44 (0)20 7397 8900 

Max Gould, Giles Balleny (Corporate Finance)

Michael Johnson (Sales)

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by enabling medical devices with ElastEon (TM) , the world's leading long-term implantable polyurethane.

Whether it is licensing ElastEon (TM) , manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

ElastEon(TM)'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:

 
 RUA Medical        End-to-end contract developer and manufacturer 
  :                  of medical devices and implantable fabric specialist. 
 RUA Biomaterials   Licensor of Elast-Eon (TM) polymers to the medical 
  :                  device industry. 
 RUA Vascular:      Development of large bore polymer sealed grafts 
                     and soft tissue patches. 
 RUA Structural     Development of tri leaflet polymeric heart valves. 
  Heart : 
 

A copy of this announcement will be available shortly at www.rualifesciences.com/investor-relations/regulatory-news-alerts .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGPBMBTMTJJBMB

(END) Dow Jones Newswires

August 31, 2021 07:32 ET (11:32 GMT)

Rua Life Sciences (LSE:RUA)
Gráfica de Acción Histórica
De Dic 2021 a Ene 2022 Haga Click aquí para más Gráficas Rua Life Sciences.
Rua Life Sciences (LSE:RUA)
Gráfica de Acción Histórica
De Ene 2021 a Ene 2022 Haga Click aquí para más Gráficas Rua Life Sciences.